Claudio Cardinali
Overview
Explore the profile of Claudio Cardinali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
3267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santoni G, Amantini C, Morelli M, Tomassoni D, Santoni M, Marinelli O, et al.
Oncotarget
. 2018 Apr;
9(24):16665-16677.
PMID: 29682176
Thymomas, tumors that arise from epithelial cells of the thymus gland, are the most common neoplasms of the anterior mediastinum, with an incidence rate of approximately 2.5 per million/year. Cytotoxic...
2.
Amantini C, Farfariello V, Cardinali C, Morelli M, Marinelli O, Nabissi M, et al.
Oncotarget
. 2017 Dec;
8(53):90766-90780.
PMID: 29207602
Autophagy and the ubiquitin-proteasome system (UPS) control thymus cell homeostasis under resting and endoplasmic reticulum (ER) stress conditions. Several evidence support a cross-talk between UPS and autophagy; abrogation of UPS...
3.
Morelli M, Amantini C, Nabissi M, Cardinali C, Santoni M, Bernardini G, et al.
Oncotarget
. 2016 Dec;
8(2):3380-3395.
PMID: 27926485
Glioblastoma is associated with a poor overall survival despite new treatment advances. Antiangiogenic strategies targeting VEGF based on tyrosine kinase inhibitors (TKIs) are currently undergoing extensive research for the treatment...
4.
Nabissi M, Morelli M, Arcella A, Cardinali C, Santoni M, Bernardini G, et al.
Oncotarget
. 2016 Nov;
7(49):81541-81554.
PMID: 27829230
The Transient Receptor Potential Vanilloid type-1 (TRPV1) channel is a non-selective cation channel belonging to the Transient Receptor Potential family; variation of its expression has been correlated to glioma progression....
5.
Nabissi M, Morelli M, Offidani M, Amantini C, Gentili S, Soriani A, et al.
Oncotarget
. 2016 Oct;
7(47):77543-77557.
PMID: 27769052
Several studies showed a potential anti-tumor role for cannabinoids, by modulating cell signaling pathways involved in cancer cell proliferation, chemo-resistance and migration. Cannabidiol (CBD) was previously noted in multiple myeloma...
6.
Amantini C, Morelli M, Nabissi M, Cardinali C, Santoni M, Gismondi A, et al.
Oncotarget
. 2016 Jul;
7(31):50180-50194.
PMID: 27367032
Bladder cancer (BC) is a common urologic tumor characterized by high risk of recurrence and mortality. Capsaicin (CPS), used as an intravesical drug for overactive bladder, was demonstrated to induce...
7.
Morelli M, Nabissi M, Amantini C, Tomassoni D, Rossi F, Cardinali C, et al.
Oncotarget
. 2016 Jun;
7(28):43654-43668.
PMID: 27248469
The Transient Receptor Potential (TRP) superfamily consists of cation-selective and non-selective ion channels playing an important role both in sensory physiology and in physiopathology in several complex diseases including cancers....
8.
Klionsky D, Abdelmohsen K, Abe A, Abedin M, Abeliovich H, Arozena A, et al.
Autophagy
. 2016 Jan;
12(1):1-222.
PMID: 26799652
No abstract available.
9.
Morelli M, Amantini C, Santoni M, Soriani A, Nabissi M, Cardinali C, et al.
Oncotarget
. 2015 Oct;
6(34):36245-59.
PMID: 26474283
Tyrosine kinase inhibitors (TKIs) including axitinib have been introduced in the treatment of renal cell carcinoma (RCC) because of their anti-angiogenic properties. However, no evidence are presently available on a...
10.
Amantini C, Morelli M, Santoni M, Soriani A, Cardinali C, Farfariello V, et al.
Oncoscience
. 2015 Jun;
2(4):395-409.
PMID: 26097873
Sorafenib, a tyrosine kinase inhibitor, has been demonstrated to exert anti-tumor effects. However, the molecular mechanisms underlying its effects on bladder cancer remain unknown. Here, we evaluated the mechanisms responsible...